Elisabeth Davis

Dr. Davis completed a B.Sc. and M.Sc. in Microbiology and Immunlogy at Dalhousie University, working in the Canadian Centre for Vaccinology to develop a live pediatric vaccine against whooping cough using the commensal bacterium Streptococcus gordonii. She then obtained her Ph.D. at the University of Alberta, in the Department of Medical Microbiology and Immunlogy. Her research focused on developing the BORG peptide-solid surface interface.